Drug Landscape ›
TERODILINE HYDROCHLORIDE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 30
Most-reported reactions
Acute Pulmonary Oedema — 3 reports (10%) Alanine Aminotransferase Increased — 3 reports (10%) Blood Chloride Decreased — 3 reports (10%) Blood Creatinine Increased — 3 reports (10%) Blood Potassium Decreased — 3 reports (10%) Blood Urea Increased — 3 reports (10%) Cardiogenic Shock — 3 reports (10%) Dizziness Postural — 3 reports (10%) Gamma-Glutamyltransferase Increased — 3 reports (10%) Heart Rate Decreased — 3 reports (10%)
Source database →
TERODILINE HYDROCHLORIDE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is TERODILINE HYDROCHLORIDE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for TERODILINE HYDROCHLORIDE in United States?
Marketing authorisation holder not available in our data.